Literature DB >> 8100861

Endothelin-1 in the human prostate: tissue levels, source of production and isometric tension studies.

P Langenstroer1, R Tang, E Shapiro, B Divish, T Opgenorth, H Lepor.   

Abstract

Endothelins mediate contractile responses in many types of vascular and nonvascular smooth muscle. The present study represents the first detailed characterization of endothelins in the human prostate. The objectives of this study were to determine the tissue levels and source of endogenous endothelin-1 (ET1) in the human prostate. The contractile effects of ET1 were also investigated using in vitro isometric tension studies. The mean tissue level of ET1 was 0.58 +/- 0.08 pg./mg. tissue wet weight. Endothelin-like activity was markedly prominent in the glandular epithelium of the human prostate, whereas minimal endothelin-like activity was observed in the prostatic stroma. Strips of human prostatic tissue were suspended in isolated tissue chambers and challenged to a concentration response of ET1. The mean EC50 and Emax for ET1 was 3.2 x 10(-8) M. and 0.12 +/- 0.02 gm. force per mm.2 cross-sectional area (CSA), respectively. Preincubation with indomethacin, terazosin, or nifedipine did not alter the concentration-dependent response to ET1. A calcium-free buffer abolished the contractile response to ET1. Thus, ET1 mediates a potent contraction of human prostatic smooth muscle that is not mediated via alpha 1 adrenergic or dihydropyridine sensitive calcium channels or prostaglandin synthesis. The presence of marked endothelin-like immunoreactivity strongly suggests a biological significance for endogenous endothelins in the human prostate.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100861     DOI: 10.1016/s0022-5347(17)35534-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

1.  Pharmacological characterization of endothelin receptor subtypes in the guinea-pig prostate gland.

Authors:  W A Lau; S L Cox; J N Pennefather; F J Mitchelson
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  Big endothelin-1 but not endothelin-1 is present in the smooth muscle stroma of the prostate gland of the rat.

Authors:  S Ventura; A Salamoussa
Journal:  J Anat       Date:  2002-02       Impact factor: 2.610

Review 3.  Endothelin receptor antagonists.

Authors:  Joel B Nelson
Journal:  World J Urol       Date:  2005-01-15       Impact factor: 4.226

4.  Endothelin-a receptor antagonists and advanced prostate cancer.

Authors:  Masood A Khan; Alan W Partin
Journal:  Rev Urol       Date:  2004

5.  [Control mechanisms of tonus of smooth muscle of the prostate and their potential significance for pharmacotherapy of benign prostatic syndrome].

Authors:  S Uckert; G Kedia; H Klocker; M Sormes; G Bartsch; U Jonas
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

Review 6.  Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).

Authors:  S Ventura; V l Oliver; C W White; J H Xie; J M Haynes; B Exintaris
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

7.  Endothelin receptor A blockade enhances taxane effects in prostate cancer.

Authors:  Ardavan Akhavan; Kevin H McHugh; Georgi Guruli; Robert R Bies; William C Zamboni; Sandra A Strychor; Joel B Nelson; Beth R Pflug
Journal:  Neoplasia       Date:  2006-09       Impact factor: 5.715

8.  [Expression of corticotropin releasing factor receptor 2 (CRFR2) in the human prostate. A new potential target for medical therapy of benign prostatic hyperplasia].

Authors:  H Tezval; A S Merseburger; M Seidler; J Serth; M A Kuczyk; M Oelke
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

9.  Transgenic mice over-expressing endothelin-1 in testis transactivated by a Cre/loxP system showed decreased testicular capillary blood flow.

Authors:  Amy C Y Lo; Maggie K L Fung; C L Au; Theobald S K Chan; Brian Sauer; Stephen S M Chung; Sookja K Chung
Journal:  Transgenic Res       Date:  2004-04       Impact factor: 2.788

Review 10.  Endothelin-1 as a target for therapeutic intervention in prostate cancer.

Authors:  E Scott Kopetz; Joel B Nelson; Michael A Carducci
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.